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The NF-kB transcription factor controls diverse bio-
logical processes. According to the classical model,
NF-kB is retained in the cytoplasm of resting cells via
binding to inhibitory, IkB proteins and translocates
into the nucleus upon their ligand-induced degrada-
tion. Here we reveal that Sef, a known tumor sup-
pressor and inhibitor of growth factor signaling, is a
spatial regulator of NF-kB. Sef expression is regu-
lated by the proinflammatory cytokines tumor
necrosis factor and interleukin-1, and Sef specifically
inhibits ‘‘classical’’ NF-kB (p50:p65) activation by
these ligands. Like IkBs, Sef sequesters NF-kB in
the cytoplasm of resting cells. However, contrary to
IkBs, Sef continues to constrain NF-kB nuclear entry
upon ligand stimulation. Accordingly, endogenous
Sef knockdown markedly enhances stimulus-
induced NF-kB nuclear translocation and conse-
quent activity. This study establishes Sef as a feed-
back antagonist of proinflammatory cytokines and
highlights its potential to regulate the crosstalk
between proinflammatory cytokine receptors and
receptor tyrosine kinases.
INTRODUCTION
Within their physiological environment, cells constantly receive
a multitude of signals, such as those emanating from growth
factors and cytokines, towhich theymust respond appropriately.
Integration of the incoming signals with internal state information
lies at the heart of cell fate decisions determining cell prolifera-
tion, differentiation, and survival (Dinarello, 2000; Pawson and
Nash, 2003). Numerous humandiseases includingmultiple forms
of cancer and developmental disorders arise from deregulationDevelopmenof this information processing, implying that the strength and
duration of the signal must be tightly controlled (Simon, 2000;
Freeman, 2000; Dinarello, 2000). An important mode of regula-
tion involves negative feedback loops (Niehrs and Meinhardt,
2002). Sef (IL-17RD) is a recently identified feedback antagonist
of receptor tyrosine kinase (RTK) signaling (Ron et al., 2008). It is
downregulated in a variety of human cancers, and loss of Sef
expression correlates with tumor aggressiveness and poor prog-
nosis, underscoring the role of Sef as a tumor suppressor gene
(Zisman-Rozen et al., 2007; Murphy et al., 2010).
Sef encodes a type I transmembrane protein that is highly
conserved in vertebrates (Ron et al., 2008). Original studies in
zebrafish embryos revealed that Sef inhibits fibroblast growth
factor (FGF) dorsalizing signals by attenuating extracellular
signal-related kinase/mitogen-activated protein kinase (ERK/
MAPK) activation (Fu¨rthauer et al., 2002; Tsang et al., 2002) in
amanner dependent on a conserved tyrosine residue in the cyto-
plasmic domain of Sef (Tsang et al., 2002). Similar to zebrafish
Sef, themouse (mSef) andhuman (hSef, alsoknownashSef-a)or-
thologs inhibit ERK/MAPK activation in response to various RTK
ligands (Ron et al., 2008); however, surprisingly, the conserved
tyrosine was dispensable for such inhibition (Torii et al., 2004;
Ziv et al., 2006). An added level of complexity is bestowed upon
mammalian Sef proteins as they also suppress FGF-mediated
activation of Akt, a downstreameffector of thePhosphatidylinosi-
tol 3-OH kinase (PI-3K) pathway (Kovalenko et al., 2003; Ziv et al.,
2006), and augment the activity of stress kinases (Yang et al.,
2004; Ziv et al., 2006). Accordingly, and depending on cellular
context, mammalian Sef proteins have the capacity to attenuate
cell proliferation or differentiation or to induce apoptosis (Kova-
lenko et al., 2003; Xiong et al., 2003; Torii et al., 2004; Yang
et al., 2004; Ziv et al., 2006). Thus far, it remains unknownwhether
Sef can regulate signals emanating from other receptor types.
The NF-kB family of transcription factors regulates diverse
biological processes, including immune and inflammatory
responses, cell survival, and cell proliferation (Hayden and
Ghosh, 2008). Aberrant NF-kB signaling has been implicated in
various pathologies, including chronic inflammation and cancertal Cell 23, 611–623, September 11, 2012 ª2012 Elsevier Inc. 611
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akis, 2009). Thus, deciphering mechanisms that control NF-kB
activity is a key for understanding basic physiological processes
and developing therapeutic strategies for various human
diseases. The NF-kB family comprises five members—p65
(RelA), cRel, RelB, p50, and p52—that can homo- or heterodi-
merize to form either transcriptionally active or repressive
NF-kB dimers, with p50:p65 being the primary mediator of NF-
kB transcriptional activity (Hoffmann and Baltimore, 2006; Hay-
den and Ghosh, 2008). In resting cells, the p50:p65 dimer exists
mostly as a cytoplasmic complex bound to inhibitor IkB proteins
(Hoffmann and Baltimore, 2006; Hayden and Ghosh, 2008).
Numerous upstream signals induce degradation of IkB proteins
following phosphorylation by the IkB kinase (IKK) complex, the
latter comprising two catalytic subunits (IKKa and IKKb) and
the regulatory subunit NEMO (NF-kB essential modulator or
IKKg; Ha¨cker and Karin, 2006). The liberated NF-kB dimer
translocates to the nucleus, where it activates the expression
of target genes including its own inhibitor, IkBa, which, once
synthesized, binds to nuclear NF-kB and exports it to the cytosol
(Hayden and Ghosh, 2008; Ferreiro and Komives, 2010).
A pilot screen aimed at discovering Sef regulators in vivo impli-
cated interleukin-1 (IL-1) as a candidate. IL-1 is a pleiotropic
cytokine produced bymany cell types. It is involved in the activa-
tion and maintenance of inflammatory responses and in cell
proliferation and differentiation, and it has been implicated in
a number of pathological conditions, including chronic inflam-
mation and cancer (Dinarello, 2009). The transcription factors
NF-kB and AP-1 play major roles in mediating IL-1-induced
cellular responses (Verstrepen et al., 2008). The goal of the
present work was to investigate the relationship between Sef
and IL-1 signaling. Our detailed analyses demonstrate that Sef
is a feedback antagonist of IL-1 signaling.Sef expression is regu-
lated by IL-1 in vitro and in vivo and that hSef specifically inhibits
IL-1-induced NF-kB activation. hSef interacts with NF-kB
(p50:p65) in resting cells by binding to the p50 nuclear locali-
zation signal (NLS) and continues to sequester NF-kB in the
cytoplasm following stimulus-induced IkBa degradation. Sef
localizes predominantly to the Golgi apparatus and early endo-
somes, and it recruits NF-kB to these organelles regardless of
cell stimulation. Our results also show that the conserved tyro-
sine, dispensable for the role of hSef in RTK signaling, is essential
for this inhibitory function and the interaction between hSef and
p50. Remarkably, hSef silencing enhances NF-kB nuclear trans-
location and consequent transcriptional activity without affecting
the upstream events leading to IkBa degradation. Altogether, our
results demonstrate that Sef attenuates NF-kB activity through
a negative feedback mechanism. Since Sef expression was
found to be regulated also by tumor necrosis factor (TNF), and
hSef inhibits TNF-induced NF-kB activation, we propose that
Sef functions as a common antagonist of proinflammatory cyto-
kine signaling.
RESULTS
Sef Is a Feedback Antagonist of IL-1 Signaling
To examine whether Sef expression is regulated by IL-1, murine
fibroblasts were stimulated with IL-1 for different time intervals,
and mSef expression was assessed by semiquantitative612 Developmental Cell 23, 611–623, September 11, 2012 ª2012 ElsRT-PCR. mSef mRNA levels were rapidly induced by IL-1, with
maximal induction observed at 15 and 30 min poststimulation
and declining after 60 min (Figure 1A). hSef expression was
also induced rapidly in IL-1-treated primary human dermal
fibroblasts, and induction was abrogated in the presence of
exogenous IL-1 receptor antagonist, IL-1Ra, (Figure 1B; Dinar-
ello, 2009). To demonstrate that IL-1 also regulates Sef in vivo,
we examined Sef expression in the skin, where IL-1 is known
to play a key role (Werner and Smola, 2001). We performed
RNA in situ hybridization on skins derived from wild-type (WT),
IL-1a/b/, and IL-1Ra/ mice (Horai et al., 1998), testing how
these changes affect Sef expression in the skin. In WT mice,
Sef transcripts were detected in the epidermis, dermal fibro-
blasts, and skin appendages (Figure 1C, left panels, top and
bottom). In accordance to our in vitro results, Sef expression
was dramatically elevated in the skin of IL-1Ra/ mice (Fig-
ure 1C, bottom right panel). Conversely, in skin sections
from IL-1a/b/ mice, Sef expression was reduced to varying
degrees with the highest reduction observed in the sebaceous
gland (Figure 1C, top right panel and inset). Collectively, our
results establish that IL-1 regulates Sef expression in both
murine and human cells.
Next, pathway-specific inhibitors were utilized to delineate
which of the signaling pathways activated by IL-1 mediates
Sef induction. We found that inhibitors of the NF-kB and AP-1
pathways—but not inhibitors specific to PI3K, ERK/MAPK, or
p38 MAPK pathways—can suppress IL-1-induced Sef expres-
sion in mouse fibroblasts (Figure 1D; Figure S1 available
online). These results suggest that both NF-kB and AP-1 are
required to mediate IL-1-induced Sef expression. Similar results
were obtained using human dermal fibroblasts (data not shown).
Having established that IL-1 induces Sef expression, we next
investigated whether Sef can function as a feedback antagonist
of IL-1 signaling by assessing the effect of hSef on IL-1mitogenic
activity. [3H]-thymidine incorporation assay was performed in
NIH/3T3 stable cell lines (designated NIH 3T3/hSef-a cells), in
which the expression of hSef is regulated by tetracycline (tet;
Ziv et al., 2006). As hSef abrogates the mitogenic activity of
FGFs but not serum (Ziv et al., 2006), these stimuli were used
as controls. As seen with FGF-2, hSef inhibited IL-1 mitogenic
activity (Figure 1E). These data support the existence of a nega-
tive feedback loop whereby IL-1 positively modulates Sef gene
expression and Sef attenuates IL-1 signaling.
hSef Inhibits IL-1-Induced Activation of NF-kB
To explore the mechanism underlying hSef inhibition of IL-1
signaling, we examined its effect on IL-1-induced activation of
NF-kB and AP-1. If Sef acts prior to bifurcation of IL-1R signaling
into the AP-1 and NF-kB cascades, it should inhibit activation of
both transcription factors. To test this prediction, three IL-1
responsive cell lines were transfected with hSef-encoding
plasmid along with either NF-kB or AP-1 reporter plasmids, fol-
lowed by IL-1 stimulation. We found that hSef inhibited IL-1-
induced NF-kB reporter activity in all tested cell types: NIH 3T3
and HeLa cells that express the native IL-1 receptor (IL-1R), as
well as HEK293/IL-1R cells that overexpress IL-1R (Figure 1F).
In contrast, hSef failed to inhibit IL-1-induced AP-1 reporter
activity in any of these cell lines (Figure 1G). In accordance,
hSef did not inhibit IL-1-stimulated phosphorylation of c-Junevier Inc.
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Figure 1. Sef Is a Feedback Antagonist of
IL-1 Signaling
(A and B) IL-1 induces Sef expression. RT-PCR
analysis of total RNA extracted from serum-
starved NIH 3T3 cells (A) and HDFs (B) treated with
IL-1 (10 ng/ml). Amplification was performed with
mSef- and hSef-specific primers and GAPDH
standard primers. NC, no template.
(C) IL-1 regulates Sef expression in vivo. RNA
in situ hybridization was performed on skin tissue
sections from IL1a/b/, IL-1Ra/, and control
C57BL mice using murine-specific Sef mRNA
antisense probe. The colorimetric reaction was
stopped after either 10 min (bottom panels) or
30 min (top panels). Insets depict a higher magni-
fication of a sebaceous gland within the same
section. Sense probe yielded no signal (not
shown). Bars, 10 mm.
(D) AP-1 and NF-kB mediate IL-1-induced Sef
expression. Serum-starved NIH 3T3 cells were
treated for 1 hr with specific inhibitors against one
of the following kinases: IKK (PR; 10 nM), p38
MAPK (SB; 10 nM), PI3K (LY; 20 nM), MEK (UO;
10 nM), or JNK (SP; 20 nM) and then stimulated
with 10 ng/ml IL-1 for 15 min. Sef expression was
assessed by RT-PCR analysis. See also Figure S1.
(E) hSef inhibits IL-1 mitogenic activity. Serum-
starved confluent cultures of NIH/hSef-a cells
grown with or without tet were stimulated with
serum (NBS), IL-1, or FGF-2, or left unstimulated;
then [3H]-thymidine incorporation was assessed.
Error bars indicate SD (n = 2).
(F and G) hSef suppresses NF-kB but not AP-1
activation. The indicated cells were transfected
with NF-kB or AP-1 luciferase reporter plasmid
alone or with a plasmid encoding hSef. Stimulation
was with 10 ng/ml IL-1 for 6 hr. Error bars indicate
SEM (n = 3).
(H) hSef does not suppress JNK activation. NIH/
hSef-a cells grown with or without tet were stim-
ulated with 10 ng/ml IL-1, or left unstimulated, for
the indicated time periods. Whole cell lysates were
subjected to western blot analysis using a-acti-
vated JNK (pJNK), a-hSef, or a-actin antibody, the
latter serving to monitor relative protein loading.
(I) hSef inhibits induction of NF-kB target genes.
RT-PCR was performed with Sef-, FGF-7-, and
IL-6-specific primers.
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Sef Inhibits Proinflammatory Cytokine SignalingN-terminal kinase (JNK; Figure 1H). These data reveal that, while
both AP-1 and NF-kB mediate Sef gene induction by IL-1, Sef
selectively inhibits NF-kB activation.
NF-kB activation by proinflammatory cytokines is biphasic,
consisting of a rapid-transient phase and a persistent phase
(Thompson et al., 1995; Hoffmann et al., 2002). Early responses
to cytokines aremediated by the classical p50:p65 NF-kBdimer.
As Sef expression is induced shortly after IL-1 stimulation
(Figure 1A), we speculated that it inhibits the transient phase of
NF-kB activation. To test this hypothesis, we examined the
effect of ectopic hSef on IL-1-dependent induction of endo-
genous Sef and other known early NF-kB target genes. The
expression of endogenous Sef, FGF-7, and IL-6 transcripts
was rapidly induced upon IL-1 stimulation in the absence of
hSef. In contrast, expression of these NF-kB target genes
was barely induced in response to IL-1 stimulation in the pres-Developmenence of hSef (Figure 1I). Collectively, these results further sup-
port the conclusion that Sef is a bona fide target of NF-kB and
establish Sef as a feedback antagonist of classical NF-kB. The
existence of several putative NF-kB response elements in Sef
promoter (data not shown) and a recent report of NF-kB
genome-wide binding sites (Kasowski et al., 2010) are consistent
with Sef being a direct target of NF-kB.
hSef Does Not Affect IL-1-Induced Proteolysis of IkBa
A hallmark of the canonical NF-kB response is stimulus-induced
degradation of IkBa, followed byNF-kB-dependent transcription
of the IkBa gene and subsequent IkBa protein synthesis (Ferreiro
and Komives, 2010). Therefore, hSef could inhibit NF-kB activa-
tion by preventing IL-1-induced IkBa degradation. However,
immunoblotting (IB) analysis revealed that hSef does not alter
the rapid loss of IkBa protein seen within 15 min of IL-1tal Cell 23, 611–623, September 11, 2012 ª2012 Elsevier Inc. 613
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Figure 2. Sef Inhibits NF-kB Nuclear Translocation and De Novo Synthesis of IkBa
(A) hSef does not prevent IkBa degradation but retards its de novo synthesis. Cells were treated as described in Figure 1H; whole cell lysates were subjected to
western blot analysis using the indicated antibodies. Densitometric analysis was performed using Tina software (bottom panel).
(B) hSef has no effect on IKK activation or NF-kB protein stability. Same protocol was used as described in (A). IKK activation and the levels of p65, p50, and p105
were evaluated using a-phosphospecific IKK (pIKKa/b), a-p65, and a-p50 antibodies, respectively; the latter also detects p105.
(C) hSef inhibits NF-kB activation in the presence of constitutively active (CA) forms of IKKa/b. Same protocol was used as in Figure 1F.
(D) hSef suppresses IkBa gene induction. NIH/hSef-a cells grown with or without tet were treated with 10 ng/ml IL-1 for the indicated times or left untreated. IkBa
and IkBb transcript levels were assessed by RT-PCR.
(E) hSef attenuates IL-1-induced NF-kB (p65) nuclear translocation in NIH/hSef-a cells. Cells were stimulated for 15 min with 10 ng/ml IL-1 and then analyzed by
indirect IF with p65 antibody.
See also Figure S2.
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phosphorylation of endogenous IKKa/IKKb (Figure 2B) but sup-
pressed NF-kB-dependent reporter activity in the presence of614 Developmental Cell 23, 611–623, September 11, 2012 ª2012 Elsa constitutively active form of either IKKa or IKKb (Figure 2C).
These findings suggest that hSef does not affect IL-1 signaling
events upstream to IkBa degradation.evier Inc.
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30 min of stimulation in hSef-expressing cells, its levels were
6-fold lower than those observed in the corresponding control
cultures (Figure 2A). In light of this observation, we investigated
whether hSef suppresses NF-kB-dependent de novo synthesis
of IkBa mRNA. Indeed, hSef inhibited IL-1-induced synthesis
of IkBa mRNA without affecting the expression of IkBb, which
is not a target of NF-kB (Figure 2D; Thompson et al., 1995).
Collectively, our results support the premise that hSef may be
targeting NF-kB.
hSef Suppresses IL-1-Induced NF-kB Nuclear
Translocation
hSef could either promote degradation of NF-kB or inhibit its
nuclear translocation. First, we investigated whether hSef affects
expression levels of p65, p50, or p105 (the precursor of p50).
hSef, however, had no effect on the levels of these proteins
before or up to 30 min poststimulation with IL-1 (Figure 2B).
We conclude that hSef does not regulate the stability of NF-kB
proteins.
Next, we examined whether hSef influences IL-1-dependent
nuclear translocation of NF-kB. NIH 3T3/hSef cells grown in
the presence or absence of tet were stimulated with IL-1 for
15 min, and then endogenous p65 was visualized by indirect
immunofluorescence (IF). In the absence of hSef, p65 nuclear
translocation peaked 15 min post-IL-1 stimulation (Figure 2E),
a time point at which IkBa degradation was maximal (Figure 2A).
In striking contrast, hSef inhibited the nuclear translocation of
p65 in over 98%of the IL-1-stimulated cells (Figure 2E). Similarly,
hSef suppressed nuclear translocation of p65 in HeLa cells (Fig-
ure 4D). These results were further confirmed by cell fraction-
ation and western blotting (Figure S2A), clearly demonstrating
that hSef inhibits IL-1-induced NF-kB nuclear translocation.
Divergent activating signals converge on the IKK complex to
activate NF-kB (Ha¨cker and Karin, 2006; Verstrepen et al.,
2008). As Sef acts downstream to IkBa degradation, we specu-
lated that its antagonistic effect may not be unique to IL-1
signaling. Indeed, we found that TNF upregulates Sef expression
and Sef, in turn, inhibits TNF-induced NF-kB nuclear transloca-
tion and transcriptional activity (Figures S2B–S2F). These results
clearly indicate that Sef is also a feedback antagonist of TNF,
implying that Sef regulation of NF-kB activity through this
currently identified autoregulatory feedback loop may be
a general mechanism for the modulation of proinflammatory
cytokine signaling.
hSef Interacts with Components of the Canonical NF-kB
Pathway
Since hSef lacks any known enzymatic activity, we reasoned that
it might function by interacting with NF-kB. Therefore, we exam-
ined which of the NF-kB subunits interacts directly with hSef.
Coimmunoprecipitation (coIP) assays were performed on
HEK293/IL-1R extracts coexpressing hSef with either p50 or
p65. The results indicated that only p50 coprecipitated with
hSef (Figures 3A and 3B). hSef was also found in a complex
with p50 in reciprocal coIP experiments (Figure 3D, right panel),
and cell stimulationwas not essential for this interaction (data not
shown). As further confirmation of these results, we performed
cell-free binding assays. Recombinant hSef was pulled-downDevelopmenfrom stimulated and unstimulated 293/IL-1R cells and allowed
to bind in-vitro-translated 35S-labeled p50 or p65 (IVT-p50, and
IVT-p65, respectively). hSef specifically interacted with IVT-
p50, and hSef proteins from both stimulated and unstimulated
cells were able to bind equally well with p50 (Figure 3C). To
ascertain the physiological relevance of these findings, we
tested whether Sef exists in vivo in a complex with p50 by coIP
experiments utilizing an antibody that recognizes the extracel-
lular domain of hSef whose specificity was confirmed in prelim-
inary experiments (Figure 3E). Indeed, as shown in Figure 3F
(right panel), hSef antibodies coprecipitated endogenous p50
along with hSef from nonstimulated HEK293 cell extracts.
Although hSef failed to directly associate with p65, it was
found in a complex with p65 when both p50 and p65 were coex-
pressed (Figure 3D, left panel). These data indicate that p50
bridges between hSef and p65 and that hSef does not disrupt
p50:p65 dimerization. Next, we tested whether hSef colocalizes
with p65. HeLa cells were cotransfected with hSef and p65
expression constructs, and colocalization was analyzed by IF
and confocal microscopy. In these cells, hSef localizes predom-
inantly to early endosomes and the Golgi apparatus (Figure S3A)
as previously observed in other cell types (Torii et al., 2004; Ren
et al., 2007). Colocalization between hSef/p65 was readily de-
tected in both resting and IL-1-stimulated HeLa cells (Figure 3G).
Similar colocalization was observed between ectopic hSef and
endogenous p65 (Figure 4E). Collectively, our results provide
compelling evidence that Sef interacts with classical NF-kB via
direct binding to p50, irrespective of cell stimulation.
In resting cells, NF-kBproteins reside within a largemultisubu-
nit complex containing IKKs and IkBs (Heilker et al., 1999). Since
hSef interaction with NF-kB does not require ligand stimulation,
we explored whether it also interacts with upstream components
of the canonical NF-kB pathway. To this end, hSef was found
associated with IkBa and IKKb but not with IKKa or IKKg in
coIP experiments (Figures S3B–S3E). These results raise the
possibility that Sef might also interact directly with IKKb and
IkBa. Studies are underway to further explore this option.
Sef Association with p50 Is Essential for Sef Function
and Requires Intact p50-NLS
Binding of IkBa to classical NF-kB masks the NLS on p65, while
leaving the NLS of p50 exposed (Ghosh and Karin, 2002). As Sef/
p50 association exists in resting cells, we asked whether it is
mediated through the p50-NLS. To test this, we coexpressed
hSef with a p50-NLS mutant, in which the two residues shown
to be necessary for p50-NLS function (K363 and R364) were
mutated (Fagerlund et al., 2005). CoIP assays revealed that the
mutations significantly reduced p50 affinity for hSef but had no
effect on the binding of p50 to p65 (Figure 4A; data not shown).
Since the exposed p50-NLS is thought to allow shuttling of the
IkBa/NF-kB complex into the nucleus in resting cells (Ghosh
and Karin, 2002), Sef binding to the p50-NLS might serve to
restrict this transport. Next, we asked if the interaction with
p50 is obligatory for Sef inhibitory function by examining the
effect of hSef on NF-kB reporter activity in WT versus p50/
mouse embryonic fibroblasts (MEFs). hSef failed to inhibit IL-1-
inducedNF-kB reporter activity in the absenceof p50 (Figure 4B).
This establishes the obligatory role of the Sef/p50 interaction for
mediating Sef inhibitory function and implies that themechanismtal Cell 23, 611–623, September 11, 2012 ª2012 Elsevier Inc. 615
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Figure 3. Sef Associates with NF-kB via Binding to p50
(A–C) hSef interacts with p50 but not with p65 in coIP (A and B) and in cell-free binding (C) assays.
(D) p65 coprecipitates with hSef in the presence of p50. For the coIP, 293/IL-1R cells were transfected with the indicated combinations of constructs, and whole
cell lysates were either immunoblotted (IB) or immunoprecipitated (IP) with the indicated antibodies. For the cell-free binding assays, hSef-Myc or Flag-p65
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masking of the p50-NLS.
Sef ‘‘Conserved’’ Tyrosine Residue Is Essential for
Inhibiting Cytokine Signaling
Since the conserved tyrosine (Y330 in hSef) is dispensable for
hSef inhibition of RTK signaling (Torii et al., 2004; Ziv et al.,
2006), we speculated that it might play a role in the context of
proinflamatory cytokine signaling. To test this hypothesis, we
examined the ability of hSefY330Fmutant (Ziv et al., 2006) to inhibit
proinflammatory cytokine-induced NF-kB activation. We found
that the mutant protein was unable to inhibit NF-kB activation
in response to IL-1 (Figure 4C) or TNF (data not shown) in both
NIH 3T3 and HeLa cells. Accordingly, the hSefY330F protein failed
to prevent IL-1-induced NF-kB nuclear translocation (Figure 4D).
To further substantiate these findings, we compared the localiza-
tion of WT andmutant Sef with endogenous NF-kB (p65) in HeLa
cells. As shown in Figure 4E, part of endogenous p65 was colo-
calized with hSef at the Golgi apparatus and early endosomes
regardless of cell stimulation. Such partial colocalization might
be expected because only a fraction of cytoplasmic p65 is bound
to the IkBa protein (Ghosh and Karin, 2002; Basak et al., 2007).
Similar to WT-Sef, the mutant protein was localized at the Golgi
apparatus, but unlike hSef, the mutant displayed higher levels in
the plasma membrane and reduced accumulation in endocytic
vesicles, in agreement with an earlier report (Ren et al., 2007).
Despite the fact that the mutant protein retained Golgi localiza-
tion, it failed to associate with NF-kB (p65). Given the essential
role of p50 in mediating Sef interaction with classical NF-kB,
we reasoned that the Y330F mutation might impair binding of
hSef to p50. Indeed, hSefY330F failed to associate with p50 in
coIP assays (Figure 4F). Moreover, in vitro binding assays per-
formed with increasing concentrations of hSef proteins and fixed
amounts of IVT-p50, revealed that the Y330F mutation substan-
tially reduced binding affinity of hSef to p50 (Figure 4G). Taken
together, these results reveal the importance of the conserved
tyrosine residue in mediating Sef cytoplasmic sequestration of
NF-kB and further imply that low binding affinity to NF-kB, rather
than partially altered subcellular distribution, underlies the failure
of SefY330F to colocalize with NF-kB.
It was notable that NF-kB reporter activity is slightly elevated in
the presence of hSefY330F as compared to control (Figure 4C).
This suggested that the Y330F mutation conferred a dominant
negative effect in the cellular context. Apparently, when coex-
pressed with hSef, the hSefY330F mutant reversed the inhibition
of IL-1-induced NF-kB activation in a dose-dependent manner
(Figure 5A). As hSef is capable of forming oligomeric complexesproteins were pulled down from transfected 293/IL-1R extracts using a-tag anti
densitometry. Equal amounts of the immobilized hSef or p65 proteins were incu
(E) Comparison of hSef protein levels in human cell lines with ectopic hSef levels. W
and 2), HEK293 cells (lane 3), and HEK293 cells transfected with 0.4 mg hSef c
extracellular domain of hSef and then with anti-tubulin. HA847 cells are negative h
(pep) used for immunization.
(F) hSef exists in vivo as a complex with p50. Whole extracts from unstimulated H
carried out on the clarified lysates with the aforementioned a-hSef antibody (+). Le
Analysis of the immunoprecipitates by immunoblotting (IB) with a-p50 and then
(G) hSefcolocalizeswithNF-kB (p65).HeLacellswere transfectedwith0.5mgof the i
and analyzed by indirect IF/confocal microscopy with a-Flag alone or by double im
See also Figure S3.
Developmen(Yang et al., 2003), we hypothesized that the dominant negative
effect could result from the formation of inactive heterodimers
between WT-hSef and hSefY330F. To test this, 293/IL-1R cells
were cotransfected with Flag-hSef and Myc-hSefY330F con-
structs and coimmunoprecipitated with Flag antibodies to
exclude hSefY330F homomeric complexes from being precipi-
tated. A major immunoreactive band of 120 kDa, compatible
with hSef monomers, was detected with either Flag or Myc
antibodies, clearly indicating that hSefY330F associates with
WT-hSef. A minor band with a molecular weight (MW) of WT-
Sef homodimers or WT-hSef/hSefY330F heterodimers (240 kDa)
was also detected, despite the denaturing conditions of electro-
phoresis (Figure 5B, middle and bottom panels). In cell-free
binding assays, WT-hSef/hSefY330F heterodimers exhibited
dramatically reduced binding affinity to IVT-p50 compared to
WT-hSef (Figure 5C). These results demonstrate that heterodi-
merization of hSefY330F with WT-hSef prevents binding of the
native protein to NF-kB and further indicate that the Sef func-
tional unit, at least in the context of proinflammatory cytokine
signaling, is a dimer.
Sef Inhibits Growth-Factor-Induced NF-kB Activation
Independently of Its Y330 Residue
Since growth factors can also activate NF-kB, we asked whether
the Y330 residue is required for hSef to inhibit this process. To
date, there have been no other reports of Sef affecting NF-kB
activation in the context of growth factor signaling. NF-kBactiva-
tion in response to growth factors is mediated by Akt (Vander-
moere et al., 2005; Niu et al., 2007). Since Sef suppresses
FGF-induced Akt phosphorylation, we suspected it might also
inhibit growth factor-mediated NF-kB activation (Kovalenko
et al., 2003; Ziv et al., 2006). We also speculated that the
Y330F mutation would not affect this specific activity, since the
mutant maintains Sef’s ability to inhibit RTK downstream effec-
tors (Ziv et al., 2006; Ren et al., 2007). Indeed, both hSef and
hSefY330F effectively inhibited NF-kB-dependent reporter activity
upon FGF stimulation (Figure 4H). These results reinforce the
selective requirement of the conserved tyrosine residue for Sef
inhibition of proinflammatory cytokine signaling and underscore
that hSef’s point of action leading to NF-kB inhibition differs
between RTK and cytokine receptor signaling.
Endogenous hSef Inhibits IL-1-Dependent Cell
Proliferation, NF-kB Nuclear Translocation,
and Transcriptional Activity
Having established the consequences of overexpressing hSef,
we examined the converse situation; namely, the effect ofbodies, and their relative amounts were normalized following SDS-PAGE and
bated with IVT-p50 or IVT-p65.
hole extracts from human ovarian carcinoma cell lines HA847 and 44S (lanes 1
onstruct (lane 4) were immunoblotted with an antibody directed against the
Sef mRNA (data not shown). Sef signals were competed out by the Sef peptide
EK293 cells were clarified by incubation with IgG-coated beads (), and IP was
ft panel: Detection of Sef and p50 in HEK293whole extracts (WCL). Right panel:
with a-hSef.
ndicatedexpressionplasmids.Cellswerestimulatedwith10ng/ml IL-1 for15min
munostaining with a-hSef/a-Flag (100 cells were analyzed; scale bar, 5 mm).
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Figure 4. The hSef-Conserved Tyrosine Residue and the p50-NLS Are Essential for hSef Mediated Inhibition of Proinflammatory Cytokine
Signaling
(A) p50-NLS mutations K363A/R364A (p50 NLS-M) impair binding of p50 to hSef. Same coIP protocol as in Figure 3 legend.
(B) p50 is essential for hSef inhibitory function. NF-kB reporter activity was assayed in HeLa cells, WT, and p50/ MEFs.
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Figure 5. SefY330F Associates with WT-Sef
and Prevents Binding of WT-Sef to p50
(A) hSefY330F abrogates hSef inhibition of NF-kB.
Reporter assays were performed in NIH 3T3 as
indicated in the Figure 1F legend.
(B) Dimerization between WT-Sef and hSefY330F.
293/IL-1R cells were transfected with Flag-Sef
alone or together with Myc-hSef-aY330F (1:3
ratio, respectively). Whole extracts were immu-
noprecipitated with a-Flag antibodies, and immu-
noblotting was performed with the indicated
antibodies. M and D denote monomers and
dimers, respectively.
(C) hSef/hSefY330F heterodimers exhibit substan-
tially reduced binding affinity to p50. 293/IL-1R
cells were transfected with Flag- hSef alone or
along with 3- and 5-fold excess of Myc-tagged
hSefY330F. IP was with a-Flag antibodies, and
amounts of immobilized proteins were normalized
by immunoblotting with a-Sef antibodies and
densitometry. Presence of heterodimers was
confirmed by probing with a-Myc and a-Flag
antibodies. Binding to IVT-p50 was carried out
with two different Sef-Flag concentrations (equiv-
alent to 2/10 and 4/10 lysate from a 60 mm plate)
and 4/10 lysate for the Sef-Flag/SefY330F immu-
noprecipitates from two individual IPs.
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Sef Inhibits Proinflammatory Cytokine Signalingknocking down endogenous Sef. HeLa stable lines in which hSef
expression was specifically knocked down were previously
described (Ziv et al., 2006). These cells (termed Sef-Sh cells)
and the corresponding control cultures (termed Ct-Sh cells)
were initially checked for their proliferation response to IL-1. In
line with Sef functioning as a feedback antagonist of IL-1, Sef-
silencing accelerated proliferation of HeLa cells by 2- to 3-fold
in serum-free conditions following exogenous ligand stimulation
(Figure 6A). These results establish that endogenous hSef
constrains IL-1-induced cell proliferation. It is noteworthy that
dermal fibroblasts from Sef knockout mice also exhibit an
increased proliferation rate in response to IL-1 as compared to
their WT counterparts (http://www.mmrrc.org/strains/32387/
032387.html).
As Sef restricts the canonical NF-kB response to inflammatory
stimuli, we reasoned that Sef silencing should result in hyper-
responsive NF-kB activation. To test this, cells were treated
with various IL-1 concentrations or left untreated, and both
NF-kB localization and activity were assessed. In unstimulated
cells, no increase in NF-kB nuclear localization was observed
following hSef knockdown (Figures 6B and 6C). This was(C) hSefY330F failed to inhibit IL-1-induced NF-kB reporter activity. Reporter assa
(D) hSefY330F fails to inhibit NF-kB (p65) nuclear translocation. HeLa cells were t
10 ng/ml IL-1 for 15min, double immunostained with a-Myc and a-p65 antibodies
indicate SD (n = 2).
(E) WT hSef, but not hSefY330F, colocalizes with endogenous NF-kB(p65). HeLa
constructs. Cells were stimulated with 10 ng/ml IL-1 for 15 min and analyzed
a-Myc/a-p65 antibodies. Arrows point to the Golgi apparatus. Scale bar, 20 mm.
(F and G) The Y330F mutation reduces hSef binding affinity to p50. For the coIP as
293/IL-1R cells. For the in vitro binding (G), hSef proteins were pulled down fro
described in the Figure 3 legend. Then, binding to IVT-p50 was performed with
60 mm cell extract). Densitometric analysis (G, bottom) was performed using Tin
(H) Y330 is dispensable for hSef inhibition of FGF-induced-NF-kB reporter activit
described in Figures 1F and 1G. Error bars indicate SEM (n = 3).
Developmenexpected as NF-kB would be still held captive in the cytoplasm
via the bound IkBa (Ghosh and Karin, 2002; Ferreiro and
Komives, 2010). In Ct-sh cells stimulated with 2, 5, and 7 ng/ml
of IL-1, nuclear translocation of NF-kB was observed in 15%,
35%, and 45% of cells, respectively. In striking contrast, in
Sef-Sh cells, nuclear translocation was seen in 60% of the cells
stimulated with the lowest IL-1 concentration and in over 95%
of cells stimulated with 5 or 7 ng/ml of IL-1 (Figures 6B and
6C). In accordance with the increased ligand-induced NF-kB
nuclear translocation seen in Sef-Sh cells, NF-kB-dependent
reporter activity was also dramatically enhanced in these
cells upon IL-1 stimulation (Figure 6D; 4.5-fold higher than
Ct-Sh cells). Since IL-1-induced AP-1 transcriptional activity
and the upstream events leading to IkBa degradation were not
affected by Sef overexpression, we expected that Sef knock-
down would not alter these cellular responses to IL-1. Indeed,
neither AP-1 activity nor IKK phosphorylation or IkBa degrada-
tion were changed in IL-1-stimulated Sef-Sh cells (Figures 6E
and 6F). Thus, the consequences of silencing endogenous Sef
are highly specific and fully corroborate the results of Sef
overexpression.ys were performed as described in Figure 1F.
ransfected with 0.1 mg of the indicated constructs. Cells were stimulated with
, and analyzed by IF/confocal microscopy (>500 cells were counted). Error bars
cells were transfected with 0.1 mg of the Myc-tagged wt-Sef or the SefY330F
by indirect IF/confocal microscopy following double immonostaining with
say (F), HA-p50 was coexpressed with the indicated Myc-tagged constructs in
m transfected 293/IL-1R cells, and their relative amounts were normalized as
increasing amounts of the hSef proteins (equivalent to 1/10, 2/10, and 3/10 of
a software. Error bars indicate SD (n = 3).
y. Cells were stimulated with 25 ng/ml FGF2, and the assay was performed as
tal Cell 23, 611–623, September 11, 2012 ª2012 Elsevier Inc. 619
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Figure 6. Endogenous hSef Inhibits IL-1-Dependent Cell Proliferation and NF-kB Activation
(A) Sef knockdown accelerates IL-1-induced HeLa cell proliferation. The assay was carried out as described in Experimental Procedures in hSef shRNA
knockdown cells (Sef-sh) and the corresponding control cells (Ct-sh). Error bars indicate SD (n = 3).
(B and C) hSef knockdown increases nuclear translocation of NF-kB-p65 following IL-1 stimulation. HeLa Sef-sh and Ct-sh cells were treated with the indicated
concentrations of IL-1 for 15 min and immunostained with a-p65 antibody. A total of 250 cells from each sample were microscopically examined. Representative
images of cells stimulated with 5 ng/ml IL-1 are shown in (C).
(D and E) hSef knockdown enhances IL-1-induced NF-kB but not AP-1 reporter activity. HeLa Sef-sh and Ct-sh cells were transfected with either NF-kB or AP-1
luciferase reporter constructs and stimulated with the indicated concentration of IL-1; whenmonitoring AP-1 activation, cells were stimulated with 7.5 ng/ml IL-1.
(F) hSef knockdown does not affect IkBa degradation or IKKa/b phosphorylation. HeLa Sef-sh and Ct-sh cells were stimulated with 7.5 ng/ml for the indicated
times or left unstimulated. Whole cell lysates were subjected to immunoblotting using the indicated antibodies.
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The present findings expand Sef function as a feedback antag-
onist to include proinflammatory cytokine signaling and high-620 Developmental Cell 23, 611–623, September 11, 2012 ª2012 Elslight Sef as the only known RTK inhibitor capable of such
activity. While investigating the mechanism by which Sef inhibits
proinflammatory cytokine signaling, we discovered a negative
regulatory circuit for the spatial control of NF-kB. To summarizeevier Inc.
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Figure 7. A Model of Sef Action
(A) In the absence of Sef, classical NF- kB is
sequestered in the cytoplasm of resting cells
via binding to the inhibitor IkBa, and following
ligand-induced degradation of the inhibitor, NF-kB
freely translocates to the nucleus, where it regu-
lates target gene expression. In cells expressing
Sef, both IkBa and Sef regulate cytoplasmic
sequestration of NF-kB in resting cells. Upon cell
stimulation, IkBa is rapidly degraded while Sef
remains bound to a significant fraction of NF-kB
and thereby attenuates NF-kB nuclear trans-
location. IkBa and Sef, both targets of NF-kB,
cooperate in terminating the NF-kB response;
newly synthesized IkBa enters the nucleus and
exports NF-kB to the cytoplasm, and newly
synthesized Sef, in turn, sequesters the exported
IkBa/NF-kB complex.
(B) Both FGF and proinflammatory cytokine signaling converge on the IKK complex to activate NF-kB, which induces Sef expression as well as proinflammatory
cytokines (IL-1, TNFa) and FGFs (e.g., FGF2/FGF7). Sef, in turn, inhibits both FGF- and proinflammatory cytokine-induced NF-kB activation.
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Sef Inhibits Proinflammatory Cytokine Signalingour data, we propose the following working model: Sef, via
direct binding to p50, sequesters the IkBa/NF-kB complex in
the cytoplasm of resting cells. Upon stimulation and IkBa
degradation, Sef retains a pool of NF-kB complexes in the
cytoplasm, thus regulating the extent of the nuclear transloca-
tion (Figure 7A). Overall, our data are consistent with a com-
petitive mechanism of inhibition whereby the relative ratio of
Sef to NF-kB, and signal strength, modulates the extent of
the NF-kB response. Moreover, by virtue of Sef’s capacity to
modulate RTK signals converging on the IKK complex, it can
potentially regulate crosstalk between proinflammatory cyto-
kine receptors and RTKs (Figure 7B). Sef’s ability to control
NF-kB activation in response to distinct stimuli combined with
its ubiquitous expression in mammalian tissues (Ron et al.,
2008) places Sef as a central modulator of the multitude of
responses triggered by NF-kB.
To date, the three major canonical IkBs (a, b, and V) and
noncanonical nfkb2/p100 are considered the primary regulators
of nucleocytoplasmic localization of classical NF-kB (Ghosh and
Karin, 2002; Basak et al., 2007; Hayden and Ghosh, 2008). Our
data add another level of complexity to this scenario. To our
knowledge, Sef is the only protein to share no structural similarity
with IkBs, but like IkBs, is capable of interacting with latent
NF-kB. However, even though both IkBa and Sef inhibit nuclear
translocation of theNF-kBcomplex, substantial differences exist
in their mode of action. First, IkBa is a soluble protein that
shuttles in and out of the nucleus and therefore is able to interact
with nuclear NF-kB. By contrast, Sef is a membrane-bound
protein confined mainly to the Golgi apparatus and early endo-
somes; thus, it can only interact with the cytoplasmic pool of
NF-kB. Second, while IkBs are dedicated inhibitors of NF-kB
signaling, Sef also regulates various RTK pathways. Third, while
IkBa acts like a molecular binary (‘‘on/off’’) switch, which is
turned off by rapid degradation upon ligand stimulation, Sef
remains bound to a large fraction of NF-kB in stimulated cells
and primarily functions to constrain the extent of the NF-kB
response. Hyperresponsive NF-kB activation can result in
expression of inflammatory genes in cells that do not normally
express such genes (Basak et al., 2007), and excessive and pro-
longed activation of NF-kB is implicated in various pathologiesDevelopmen(Natoli and Chiocca, 2008; Naugler and Karin, 2008; Pasparakis,
2009). Therefore, this Sef-mediated mechanism may represent
an effective mean for limiting excessive NF-kB activity. Con-
sistent with this notion is a recent online report indicating that
Sef null mice exhibit an elevated number of peripheral blood
monocytes and inflammation in several organs including the
liver (http://www.mmrrc.org/strains/32387/032387.html; Tang
et al., 2010).
Mounting evidence suggests that crosstalk between different
signaling pathways is necessary for modulating cellular
responses to external stimuli. The potential for crosstalk among
inflammatory and growth factor signals is of significance
because they affect a range of similar biological processes
such as cell proliferation and survival, tissue remodeling, and
inflammatory responses (Werner and Grose, 2003; Pasparakis,
2009; Presta et al., 2009; Crosby and Waters, 2010). In the
skin, for example, where Sef expression is regulated by IL-1
(as shown in the present work), it is well established that a
positive paracrinic feedback loop between FGFs and proinflam-
matory cytokines controls epidermis formation and homeo-
stasis (Maas-Szabowski et al., 2000). Since Sef functions along
both the cytokine and growth factors pathways, it is furnished
with the capacity to modulate not solely each pathway but
also their emanating crosstalk. This feature is crucial for
adequate integration of intracellular signaling and the proper
cellular response as well as for intercellular communication
by regulating the paracrine/autocrine loops of cytokines and
growth factors.
Our results have also important implications in the context of
cancer biology. Thus far, hSef downregulation in human cancers
was thought to only augment RTK signaling (Ron et al., 2008).
However, our findings point to an additional mechanism by
which hSef inactivation might contribute to tumorigenesis by un-
leashing a full-blown NF-kB response, which is a known feature
of many cancers (Basse`res and Baldwin, 2006; Naugler and
Karin, 2008). Thus, deciphering the mechanisms regulating Sef
activity will shed light on the link between inflammation and
cancer and provide important insights, which could be exploited
to advance Sef-based approaches for cancer therapy and
chronic inflammation.tal Cell 23, 611–623, September 11, 2012 ª2012 Elsevier Inc. 621
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Reagents, Antibodies, and Constructs
IL-1a and TNF-a were from Peprotec. FGFs and hSef antibodies were
produced as previously described (Reich-Slotky et al., 1995; Preger et al.,
2004). IL-1Ra (1 mg/ml) was from Amgen Biochemicals. Antibodies directed
against Actin (sc-1615), c-Myc-tag (9E10, sc-40), IkB-a (sc-371), pJNK
(sc-822), p65 (sc-372), p50 (sc-7178), and HA-tag (sc-805) were from Santa
Cruz Biotechnology. Anti-IKKa/b (2681) was from Cell Signaling Technology,
a-Flag (F3165) was from Sigma-Aldrich, and a-hSef directed against human
Sef extracellular domain was from R&D Systems. Fluorescein isothiocya-
nate-conjugated goat anti-rabbit immunoglobulin G (IgG) was from ICN, and
rhodamine-red-X-conjugated goat anti-mouse IgG was from Jackson Immu-
noResearch. Pharmacological inhibitors SB203580 (SB), LY294002 (LY),
UO294002 (UO), SP600125 (SP), and JNK Inhibitor I (Ji) were from Millipore;
6- amino-4-quinazoline (Ai) was from Calbiochem; and Parthenolide (PR)
was from Sigma Aldrich. Myc- and Flag-tagged hSef-a and hSef-aY330F
expression vectors were previously described (Yang et al., 2003; Preger
et al., 2004; Ziv et al., 2006).
Cell Cultures and Transfections
hSef Tet-off cell lines (NIH 3T3/hSef-a) and HeLa cells stably expressing hSef
shRNAwere previously described (Ziv et al., 2006). NIH 3T3 cells and NIH 3T3/
hSef-a cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10%newborn calf serum (NBS). NIH 3T3/hSef-a cells were
grown in the presence of 1 mg/ml tet, which was removed 16 hr prior to con-
ducting the experiments. Sef-siRNAs targeting sequence, construction of
Sef sh-RNA targeting plasmids for stable transfection, and specificity valida-
tion were as described (Torii et al., 2004; Ziv et al., 2006). HeLa cells, HDFs,
MEFs, HA847 and 44S human carcinoma cell lines were maintained in
DMEM supplemented with 10% fetal bovine serum (FBS), and HEK293IL-1R
cells (Cao et al., 1996) were grown in DMEM containing 5% FBS. For coIP,
cells were transfected by using microporator (Invitrogen) and seeded on to
60 mm plates for 16–24 hr; for IF and luciferase assays, cells were transfected
with DreamFect reagent (OZ Biosciences) according to the manufacturer’s
protocol.
Luciferase Assay
We transfected 2 3 105 cells with tested plasmids (0.16 or 0.5 mg hSef-a
constructs, and 0.08 mg IKKa or IKKb constructs). For testing FGF-induced
NF-kB activation in HeLa cells, cells were also transfected with 0.1 mg FGF-
receptor-1 (Preger et al., 2004). Sixteen hours posttransfection, cells were
left untreated or treated with the indicated ligands for 6 hr. Luciferase activity
in cell lysates was measured by using the luciferase assay system (Promega,
Madison, WI, USA) in a GLOMAX 20/20 luminometer. Reporter activity was
normalized to the activity of coexpressed Renilla.
Mitogenic and Proliferation Assays
Mitogenic assay in NIH/hSef-a cells, and calculation of fold increase (FI) in bio-
logical activity were performed as described (Preger et al., 2004). FI obtained in
cultures stimulated with 10% NBS in the presence of tet was set as 100%
(36,000 counts per minute). For proliferation assays, HeLa cells were seeded
at a density of 25,000 cells/35 mm plate. Cells were washed on the following
day, and fresh IL-1 was added every other day. The number of viable cells
was determined 5 days postseeding as described (Zisman-Rozen et al., 2007).
RT-PCR and RNA In Situ Hybridization
For RT-PCR, 1 mg of total RNA was reverse transcribed into cDNA by using
M-MLV reverse transcriptase (Invitrogen) with oligo random hexamers as
described (Preger et al., 2004; Grothe et al., 2008). Probe preparation and
RNA in situ hybridization conditions have been previously described (Grothe
et al., 2008). The animal experiments were approved by the Israel Institute of
Technology institutional committee and were in compliance with the Israel
Animal Welfare Act.
Immunoprecipitation, Immunoblotting, and Immunofluorescence
For IP, 23 106 cells were transfected with 2 mg of each plasmid, and the assay
was performed essentially as detailed (Preger et al., 2004). Briefly, 24 hr post-622 Developmental Cell 23, 611–623, September 11, 2012 ª2012 Elstransfection, equal amounts of cell lysates were incubated with antibody,
and immunocomplexes were captured on Protein-G Dynabeads. Following
SDS-PAGE and IB, bound antibodies were visualized by chemiluminescence.
IF was performed as described (Preger et al., 2004). Nuclear staining was done
with 10 mM DRAQ5 (Biostatus Limited). Cells were mounted in Fluoromount G
and examined using a laser scanning confocal microscope (LSM 510, Carl
Zeiss) or using a standard fluorescence microscope (Leica DMIRE2).
Cell-free Binding Assays
Tagged Sef or p65 proteins were immunoprecipitated from 293-IL-1R
extracts, and 35S-methionine-labeled p50 and p65 were synthesized in vitro
using the TNT quick-coupled transcription-translation kit (Promega, Madison,
WI, USA). The IVT proteins were then added toG protein beads bound to either
hSef or p65 proteins in pull-down buffer (Preger et al., 2004) and incubated at
4C for 1 hr. Following extensive washes, bound fractions were analyzed by
SDS-PAGE and autoradiography. In each case, 5% input is shown.
SUPPLEMENTAL INFORMATION
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